🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. DC-CIK Immunotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 mab active

    1 trial

  2. DC-VACCINE_IRSTIRCCS, Proleukin 18 x 106 UI Polvere per soluzione iniettabile o per infusione

    Istituto Gentili S.r.l.

    Stage IV colorectal cancer

    phase 2 small molecule active

    1 trial

  3. DC1 Vaccine

    United Therapeutics Europe Ltd

    Breast Cancer Female

    phase 2 mab active

    1 trial

  4. DCVax-L and T Cells

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 2 mab terminated

    1 trial

  5. DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

    The First People's Hospital of Lianyungang

    Triple-Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

  6. DEGARELIX ACETATE, ENZALUTAMIDE, DEGARELIX, ENZALUTAMIDE, DAROLUTAMIDE, RELUGOLIX, -, ENZALUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, Pluvicto 1 000 MBq/mL solution for injection/infusion, APALUTAMIDE

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  7. DEGARELIX, -, RELUGOLIX, ABIRATERONE, DEGARELIX, Luxdegalutamide, ABIRATERONE, ABIRATERONE, Abiraterone, ENZALUTAMIDE, ABIRATERONE, Enzalutamide

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  8. DOCETAXEL , AVELUMAB, FLUOROURACIL , OXALIPLATIN , CALCIUM FOLINATE

    The George Institute

    Resectable Gastric cancer (GC) or Gastroesophageal Junction cancer (GEJC)

    phase 2 small molecule active

    1 trial

  9. DOCETAXEL , Ifinatamab Deruxtecan, Raludotatug Deruxtecan

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. DOCETAXEL , PACLITAXEL , GEMCITABINE , VINORELBINE , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , Inflectra 100 mg powder for concentrate for solution for infusion, Micofenolato de mofetil Generis 250 mg Cápsulas

    AstraZeneca AB

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  11. DOXORUBICIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, CYCLOPHOSPHAMIDE , PACLITAXEL , EPIRUBICIN , CARBOPLATIN , MK-1022, CAPECITABINE , OLAPARIB

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  12. DOXORUBICIN HYDROCHLORIDE, IFOSFAMIDE, CISPLATIN, METHOTREXATE, ETOPOSIDE, MEPACT 4 mg powder for concentrate for dispersion for infusion

    Ningbo Cancer Hospital

    Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).

    phase 2 small molecule active

    1 trial

  13. DS-1062a

    Daiichi Sankyo

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  14. DS-8201a

    Daiichi Sankyo

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  15. DS-8201a

    Ningbo Cancer Hospital

    Metastatic Breast Cancer HR+, HER2-

    phase 2 small molecule active

    1 trial

  16. DURVALUMAB

    Fondazione Telethon ETS

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  17. DURVALUMAB , Ifinatamab Deruxtecan, MK-6070

    Merck Sharp and Dohme

    Small cell lung cancer

    phase 2 small molecule active

    1 trial

  18. DURVALUMAB, PACLITAXEL ALBUMIN-BOUND, Ceralasertib

    Fondazione Telethon ETS

    ADVANCED TRIPLE NEGATIVE BREAST CANCER

    phase 2 small molecule active

    1 trial

  19. DZR123, DZR123, ENZALUTAMIDE

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  20. Dabrafenib

    Novartis Pharmaceuticals

    Cancer

    phase 2 small molecule completed

    1 trial

  21. Dalpiciclib

    The First People's Hospital of Lianyungang

    Early Breast Cancer

    phase 2 small molecule active

    1 trial

  22. Darolutamide+ADT

    The First People's Hospital of Lianyungang

    Prostate Cancer

    phase 2 small molecule active

    1 trial

  23. Datopotamab deruxtecan

    Daiichi Sankyo

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  24. Datopotamab deruxtecan

    AstraZeneca AB

    Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources